|
|
|
 |
|
 |
| Dr Peter Barlis is Chief
Interventional Fellow at the
Royal Brompton Hospital,
London, UK, under the
mentorship of Professor Carlo
Di Mario. He completed his
cardiology training in Melbourne,
Australia, receiving a Fellowship
of the Royal Australasian
College of Physicians in 2004.
Following this, he undertook
training in clinical epidemiology,
biostatistics and trial design
culminating in a Master of
Public Health degree in 2005.
Dr Barlis has undergone
training in general and invasive
cardiology in addition to
undertaking substantive research
with specialised areas of interest
including the recanalisation of
chronic total occlusions and
intravascular imaging with
optical coherence tomography |
The use of drug eluting stents for coronary artery disease
Peter Barlis, MBBS, MPH,
FRACP
Jun Tanigawa, MD,
Carlo Di Mario, MD, PhD
Department of Invasive Cardiology,
Royal Brompton Hospital, London, UK
Address for correspondence:
Peter Barlis
Department of Invasive Cardiology
Royal Brompton Hospital, Sydney Street
London SW3 6NP, UK.
Tel: +44-20-7351-8616 Fax: +44-20-7351-8614
Email: P.Barlis@rbht.nhs.uk
Abstract
The growth in the availability and use of drug eluting
stents has seen the interventional cardiologist tackle
more lesions with increasing complexity and in higherrisk
patients. The single digit rates of restenosis observed
have helped propel these novel devices well ahead
of their bare metal counterparts, with applications
in bifurcation lesions, chronic total occlusions and
unprotected left main disease. Not all has come
without cost, however, and the problem of late stent
thrombosis has cast a cloud on long-term outcomes and
the optimal duration of dual anti-platelet therapy. This
review will describe the role drug eluting stents have in
contemporary interventional cardiology with a focus on
their shortcomings and possible future refinements.
|
|
|
